AzurRx BioPharma's OPTION 2 Trial Of MS1819 In Cystic Fibrosis Fails, What Next?

AzurRx BioPharma Inc.'s (AZRX) phase IIb study of MS1819 for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis did not consistently meet the primary efficacy endpoint.

from RTT - Top Story https://ift.tt/39yW5EX
via IFTTT